High-sensitivity cardiac troponin T in infants exposed to anti-Ro antibodies.

Autor:	Barsalou J; Division of Pediatric Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, Canada., Jaeggi E; Division of Pediatric Cardiology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, SickKids Hospital Research Institute, Toronto, Canada., Grosse-Wortmann L; Division of Pediatric Cardiology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, SickKids Hospital Research Institute, Toronto, Canada.; Division of Pediatric Cardiology, Department of Pediatrics, Oregon Health and Science University, Portland, OR, USA., Laskin CA; Department of Medicine, Obstetrics and Gynecology, University of Toronto, TRIO Fertility, Toronto, Canada., Adeli K; Division of Clinical Biochemistry, Department of Laboratory Medicine and Pathobiology, The Hospital for Sick Children, University of Toronto, SickKids Hospital Research Institute, Toronto, Canada., Silverman ED; Division of Pediatric Rheumatology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, SickKids Hospital Research Institute, Toronto, Canada.
Jazyk:	angličtina
Zdroj:	Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2023 Oct 03; Vol. 62 (10), pp. 3416-3420.
DOI:	10.1093/rheumatology/kead105
Abstrakt:	Objectives: Cardiac involvement in neonatal lupus erythematosis (NLE) can present as myocarditis/endocardial fibroelastosis (EFE). It is unknown whether high-sensitivity cardiac troponin T (hs-cTnT) is useful in identifying subclinical myocardial inflammation in infants exposed prenatally to anti-Ro antibodies. This study reports hs-cTnT levels in infants exposed to anti-Ro antibodies with/without cardiac NLE and reports cardiac MRI (CMR) findings in a subset of these children. Methods: The study included 45 consecutive infants exposed prenatally to anti-Ro antibodies with (n = 7) or without (n = 38) cardiac NLE, who were seen at the SickKids NLE Clinic between 2012 and 2014. Hs-cTnT levels were measured at least once, and those infants with values of ≥30 ng/l were offered the opportunity to undergo CMR. Descriptive statistics were performed. Results: Of 38 infants without cardiac NLE, 25 had a hs-cTnT level of ≥30 ng/l (including 1 of >113 ng/l); of these, 8 underwent CMR (all without myocarditis/EFE). All 7 infants with cardiac NLE had at least one hs-cTnT level of ≥30 ng/l, but only 2/7 had a level of >113 ng/l; 4/7 infants with cardiac NLE had CMR (all without myocarditis/EFE); 6/7 infants with cardiac NLE had their steroid treatment adjusted based on the trend in their hs-cTnT levels. Conclusion: Only 3/45 anti-Ro antibodies-exposed infants had hs-cTnT values outside the reference range reported in healthy infants. None of 12 infants who had CMR had subclinical myocarditis/EFE. Routine measurement of hs-cTnT in every anti-Ro antibody-exposed infant is not indicated. Further studies are needed to define the role of hs-cTnT as a biomarker for cardiac NLE. (© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu